Dorota Bojanowska-Knut

Uddevalla, O, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Use of upfront autologous stem cell transplantation in myeloma patients aged >65 years: a population-based study by the Nordic Myeloma Study Group.

Use of upfront autologous stem cell transplantation in myeloma patients aged >65 years: a population-based study by the Nordic Myeloma Study Group.

Journal: Haematologica

Published: January 31, 2025

Income and education affect prognosis and treatment in symptomatic myeloma : A population-based study on 8672 multiple myeloma patients diagnosed 2008-2021 from the Swedish myeloma registry.

Income and education affect prognosis and treatment in symptomatic myeloma : A population-based study on 8672 multiple myeloma patients diagnosed 2008-2021 from the Swedish myeloma registry.

Journal: Annals of hematology

Published: November 21, 2024

Risk of infections in multiple myeloma. A populationbased study on 8,672 multiple myeloma patients diagnosed 2008-2021 from the Swedish Myeloma Registry.

Risk of infections in multiple myeloma. A populationbased study on 8,672 multiple myeloma patients diagnosed 2008-2021 from the Swedish Myeloma Registry.

Journal: Haematologica

Published: April 12, 2024

The choice of serum-free light chain analysis method could potentially have clinical consequences for myeloma patients.

The choice of serum-free light chain analysis method could potentially have clinical consequences for myeloma patients.

Journal: EJHaem

Published: October 28, 2023

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13.

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13.

Journal: HemaSphere

Published: May 11, 2023

Improved survival in myeloma patients-a nationwide registry study of 4,647 patients ≥75 years treated in Denmark and Sweden.

Improved survival in myeloma patients-a nationwide registry study of 4,647 patients ≥75 years treated in Denmark and Sweden.

Journal: Haematologica

Published: January 10, 2022

Regional differences in treatment and outcome for myeloma patients in Sweden: A population based Swedish myeloma register study.

Regional differences in treatment and outcome for myeloma patients in Sweden: A population based Swedish myeloma register study.

Journal: Cancer reports (Hoboken, N.J.)

Published: August 01, 2021

Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries.

Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries.

Journal: European journal of haematology

Published: April 02, 2021

Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial.

Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial.

Journal: Haematologica

Published: February 13, 2020

Showing 1-9 of 9

Last Updated: 09/26/2026